HomeComparePBCRF vs JNJ

PBCRF vs JNJ: Dividend Comparison 2026

PBCRF yields 4.97% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PBCRF wins by $5943.07M in total portfolio value
10 years
PBCRF
PBCRF
● Live price
4.97%
Share price
$0.40
Annual div
$0.02
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5943.10M
Annual income
$5,721,922,799.87
Full PBCRF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — PBCRF vs JNJ

📍 PBCRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPBCRFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PBCRF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PBCRF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PBCRF
Annual income on $10K today (after 15% tax)
$422.43/yr
After 10yr DRIP, annual income (after tax)
$4,863,634,379.89/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, PBCRF beats the other by $4,863,630,393.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PBCRF + JNJ for your $10,000?

PBCRF: 50%JNJ: 50%
100% JNJ50/50100% PBCRF
Portfolio after 10yr
$2971.57M
Annual income
$2,860,963,744.64/yr
Blended yield
96.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

PBCRF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-0.1
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PBCRF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPBCRFJNJ
Forward yield4.97%2.13%
Annual dividend / share$0.02$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$5943.10M$30.3K
Annual income after 10y$5,721,922,799.87$4,689.40
Total dividends collected$5927.58M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: PBCRF vs JNJ ($10,000, DRIP)

YearPBCRF PortfolioPBCRF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,694$993.95$10,592$272.30+$1.1KPBCRF
2$14,685$2,172.56$11,289$357.73+$3.4KPBCRF
3$20,813$5,099.57$12,123$472.89+$8.7KPBCRF
4$35,779$13,509.21$13,141$629.86+$22.6KPBCRF
5$81,692$43,408.42$14,408$846.81+$67.3KPBCRF
6$272,666$185,256.39$16,021$1,151.60+$256.6KPBCRF
7$1,447,529$1,155,775.61$18,122$1,588.22+$1.43MPBCRF
8$13,017,584$11,468,727.81$20,930$2,228.20+$13.00MPBCRF
9$206,710,003$192,781,189.05$24,792$3,191.91+$206.69MPBCRF
10$5,943,102,504$5,721,922,799.87$30,274$4,689.40+$5943.07MPBCRF

PBCRF vs JNJ: Complete Analysis 2026

PBCRFStock

PT Bank Central Asia Tbk, together with its subsidiaries, provides banking products and services to individual, corporate, and small and medium enterprise customers in Indonesia and internationally. It offers savings accounts; motorcycle financing, as well as car, housing, working capital, and investment loans; mutual funds and bonds; electronic money services; credit cards; business collection services; and home and eBanking, remittance, and customer services. The company also provides investment financing, working capital financing, auto and multipurpose financing, operating lease, other financing activities, money lending and remittance, securities brokerage dealing and securities issuance underwriting, general or loss insurance, life insurance, Sharia banking, and venture capital services. As of December 2021, it operated 1,334 offices comprising 137 main branch offices; 1,105 permanent sub-branch offices; 70 mobile sub-branch offices; and 22 functional offices, as well as total 18,034 automated teller machines (ATMs) consisting of cash recycling machines and multi-functional ATMs. PT Bank Central Asia Tbk was founded in 1955 and is headquartered in Jakarta, Indonesia. PT Bank Central Asia Tbk is a subsidiary of PT Dwimuria Investama Andalan.

Full PBCRF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this PBCRF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PBCRF vs SCHDPBCRF vs JEPIPBCRF vs OPBCRF vs KOPBCRF vs MAINPBCRF vs ABBVPBCRF vs MRKPBCRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.